Replies to post #90683 on Biotech Values

[DewDiligence]

BIIB/ELN started an RRMS “switching” study of Tysabri vs Copaxone or Rebif. (See #msg-46709942 and #msg-39971611 for background on where these drugs stand commercially.)

clinicaltrials.gov entry:
http://clinicaltrials.gov/ct2/show/NCT01058005

Today’s press release:
http://finance.yahoo.com/news/Biogen-Idec-and-Elan-Enroll-bw-434267012.html?x=0&.v=1

[genisi]

Updated for Tysbari 1Q10 sales as reported yesterday by BIIB:

In the first quarter global sales of Tysabri rose 28 percent to $292 million.
As of the end of March, about 50,300 patients were on commercial and clinical Tysabri therapy worldwide. That compares with a figure of 48,800 patients as of the end of 2009.

http://uk.finance.yahoo.com/news/update-2-biogen-profit-falls-on-charges-tysabri-sales-rise-targetukfocus-e2ed5943dbeb.html